Disruption of 3CLpro protease self-association by short peptides as a potential route to broad spectrum coronavirus inhibitors

被引:2
|
作者
ElSawy, Karim M. [1 ,2 ]
Alminderej, Fahad M. [1 ]
Caves, Leo S. D. [2 ]
机构
[1] Qassim Univ, Coll Sci, Dept Chem, Buraydah, Saudi Arabia
[2] Univ York, York Cross Disciplinary Ctr Syst Anal YCCSA, York, N Yorkshire, England
来源
关键词
COVID-19; inhibitors; blind drug docking; 3CLpro dimerization; coronavirus inhibitors; RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS SIMULATION; FDA-APPROVED INHIBITORS; SARS-CORONAVIRUS; HOT-SPOTS; 3C-LIKE PROTEASE; MAIN PROTEASE; DOCKING; SARS-COV-2; RIBAVIRIN;
D O I
10.1080/07391102.2021.1996462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coronaviruses have posed a persistent threat to human health over the last two decades. Despite the accumulated knowledge about coronavirus-related pathogens, development of an effective treatment for its new variant COVID-19 is highly challenging. For the highly-conserved and main coronavirus protease 3CLpro, dimerization is known to be essential for its catalytic activity and thereby for virus proliferation. Here, we assess the potential of short peptide segments to disrupt dimerization of the 3CLpro protease as a route to block COVID-19 proliferation. Based on the X-ray structure of the 3CLpro dimer, we identified the SPSGVY126QCAMRP dodecapeptide segment as overlapping the hotspot regions on the 3CLpro dimer interface. Using computational blind docking of the peptide to the 3CLpro monomer, we found that the SPSGVY126QCAMRP peptide has favourable thermodynamic binding (DG 1/4 -5.93 kcal/mol) to the hotspot regions at the 3CLpro dimer interface. Importantly, the peptide was also found to preferentially bind to the hotspot regions compared to other potential binding sites lying away from the dimer interface (DDG=-1.31 kcal/mol). Docking of peptides corresponding to systematic mutation of the V125 and Y126 residues led to the identification of seven peptides, SPSGHAQCAMRP, SPSGVTQCAMRP, SPSGKPQCAMRP, SPSGATQCAMRP, SPSGWLQCAMRP, SPSGAPQCAMRP and SPSGHPQCAMRP, that outperform the wild-type SPSGVY126QCAMRP peptide in terms of preferential binding to the 3CLpro dimer interface. These peptides have the potential to disrupt 3CLpro dimerization and therefore could provide lead structures for the development of broad spectrum COVID19 inhibitors.
引用
收藏
页码:13901 / 13911
页数:11
相关论文
共 29 条
  • [21] Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease
    Herlah, Barbara
    Hoivik, Andrej
    Jamsek, Luka
    Valjavec, Katja
    Yamamoto, Norio
    Hoshino, Tyuji
    Kranjc, Kristof
    Perdih, Andrej
    PHARMACEUTICALS, 2022, 15 (05)
  • [22] Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLPro)
    Han, Sang Hoon
    Goins, Christopher M.
    Arya, Tarun
    Shin, Woo-Jin
    Maw, Joshua
    Hooper, Alice
    Sonawane, Dhiraj P.
    Porter, Matthew R.
    Bannister, Breyanne E.
    Crouch, Rachel D.
    Lindsey, A. Abigail
    Lakatos, Gabriella
    Martinez, Steven R.
    Alvarado, Joseph
    Akers, Wendell S.
    Wang, Nancy S.
    Jung, Jae U.
    Macdonald, Jonathan D.
    Stauffer, Shaun R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) : 2880 - 2904
  • [23] Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CLpro through high-throughput virtual screening and molecular dynamics simulation
    Liu, Wen-Shan
    Li, Han-Gao
    Ding, Chuan-Hua
    Zhang, Hai-Xia
    Wang, Rui-Rui
    Li, Jia-Qiu
    AGING-US, 2021, 13 (05): : 6258 - 6272
  • [24] Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases
    Al-Janabi, Ahmed S. M.
    Elzupir, Amin O.
    Yousef, Tarek A.
    JOURNAL OF MOLECULAR STRUCTURE, 2021, 1228
  • [25] Suggestion of active 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents using predictive QSAR model based on the combination of ALASSO with an ANN model
    Mozafari, Z.
    Chamjangali, M. Arab
    Arashi, M.
    Goudarzi, N.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (11) : 863 - 888
  • [26] In silico molecular docking and molecular dynamic simulation of potential inhibitors of 3C-like main proteinase (3CLpro) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using selected african medicinal plants
    Mustafa Alhaji Isa
    Adam Mustapha
    Sahar Qazi
    Khalid Raza
    Ibrahim Alkali Allamin
    Muhammad M. Ibrahim
    Mohammed M. Mohammed
    Advances in Traditional Medicine, 2022, 22 : 107 - 123
  • [27] In silico molecular docking and molecular dynamic simulation of potential inhibitors of 3C-like main proteinase (3CLpro) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using selected african medicinal plants
    Isa, Mustafa Alhaji
    Mustapha, Adam
    Qazi, Sahar
    Raza, Khalid
    Allamin, Ibrahim Alkali
    Ibrahim, Muhammad M.
    Mohammed, Mohammed M.
    ADVANCES IN TRADITIONAL MEDICINE, 2022, 22 (01) : 107 - 123
  • [28] Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: Homology modelling and molecular dynamic studies
    Berry, Michael
    Fielding, Burtram
    Gamieldien, Junaid
    BMC STRUCTURAL BIOLOGY, 2015, 15
  • [29] Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination
    Stefanelli, Irina
    Corona, Angela
    Cerchia, Carmen
    Cassese, Emilia
    Improta, Salvatore
    Costanzi, Elisa
    Pelliccia, Sveva
    Morasso, Stefano
    Esposito, Francesca
    Paulis, Annalaura
    Scognamiglio, Sante
    Leva, Francesco Saverio Di
    Storici, Paola
    Brindisi, Margherita
    Tramontano, Enzo
    Cannalire, Rolando
    Summa, Vincenzo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 253